Category Archives: FDA Image

FDA AdComm Agenda Covers the Bases

First of all, we are having a bit of a crisis with our crisis. As we appear to be moving into yet another wave of COVID-19 infections, and as research into a vaccine is aggressively underway, we also see serious … Continue reading

Posted in Advisory Committee Prepapartion, COVID19, Current Affairs, FDA Image, FDA Policy | Tagged | Leave a comment

FDA Credibility on the Line

In normal times, when there is no pandemic threatening our lives and livelihoods, it is essential for FDA to maintain the traditional “gold standard” in relation to the decision-making process for the approval of new treatments. That standard is even … Continue reading

Posted in FDA Image, FDA Policy | Tagged | Comments Off on FDA Credibility on the Line

What They Said – A Look Back at FDA Press Releases First Half of 2020

Each year, midway through it all, I take a look back to see what FDA has been talking about and compare it to the year before to see how things may have changed. I’m a little late at getting to … Continue reading

Posted in FDA Image | Tagged | Comments Off on What They Said – A Look Back at FDA Press Releases First Half of 2020

FDA to Hold Virtual AdComm

I don’t usually publish the scheduling of an AdComm with a blog posting. But this one merits one. With fewer than the usual minimum of fifteen days’ notice, FDA has scheduled an FDA Advisory Committee meeting of the Cardiovascular and … Continue reading

Posted in Advisory Committee Prepapartion, FDA Image, FDA Policy | Tagged , , | Comments Off on FDA to Hold Virtual AdComm

Impact of COVID-19 on Regulatory Enforcement and Approvals

The impacts of the COVID-19 pandemic bring change shifts the status quo on a daily basis with both breadth and depth. Everything we as individuals and as a society would normally do is undergoing change. FDA regulatory oversight is one … Continue reading

Posted in Current Affairs, FDA Image, FDA Policy | 1 Comment